Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Waldemar Ślizień"'
Autor:
Bogdan Biedunkiewicz, Leszek Tylicki, Waldemar Ślizień, Monika Lichodziejewska-Niemierko, Małgorzata Dąbrowska, Alicja Kubanek, Sylwia Rodak, Karolina Polewska, Piotr Tylicki, Marcin Renke, Alicja Dębska-Ślizień
Publikováno v:
Vaccines, Vol 10, Iss 3, p 433 (2022)
The aim of this study was to analyze the waning of anti-spike (S) antibodies after mRNA vaccination against COVID-19 in maintenance dialysis patients, and to assess the safety and effectiveness of the complementary third dose. This was a prospective,
Externí odkaz:
https://doaj.org/article/c1c35b19166c41ac95d40c9f9457d51e
Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project
Autor:
Karolina Polewska, Piotr Tylicki, Bogdan Biedunkiewicz, Angelika Rucińska, Aleksandra Szydłowska, Alicja Kubanek, Iwona Rosenberg, Sylwia Rodak, Waldemar Ślizień, Marcin Renke, Alicja Dębska-Ślizień, Leszek Tylicki
Publikováno v:
Medicina, Vol 57, Iss 7, p 732 (2021)
Background and Objectives: The Pfizer-BioNTech (BNT162b2) COVID-19 mRNA vaccine has demonstrated excellent efficacy and safety in phase 3 trials. However, no dialyzed patients were included, and therefore safety data for this patient group is lacking
Externí odkaz:
https://doaj.org/article/167d14ae29b744f388555087c39ed8e7
Autor:
Bogdan Biedunkiewicz, Leszek Tylicki, Ewelina Puchalska-Reglińska, Małgorzata Dąbrowska, Waldemar Ślizień, Alicja Kubanek, Maciej Rąbalski, Maciej Kosiński, Maciej Grzybek, Marcin Renke, Alicja Dębska-Ślizień
Publikováno v:
European Journal of Translational and Clinical Medicine. 5:12-16
Autor:
Karolina Polewska, Alicja Dębska-Ślizień, Piotr Tylicki, Leszek Tylicki, Bogdan Biedunkiewicz, Iwona Rosenberg, Sylwia Rodak, Waldemar Ślizień, Małgorzata Dąbrowska
Publikováno v:
Polish Archives of Internal Medicine.
Introduction: There is an urgent need to check the efficacy of SARS-CoV-2 vaccination among hemodialysis patients who are known to have large abnormalities of acquired immunity and a catastrophic risk of death from COVID-19. Objectives: In this cross
Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project
Autor:
Sylwia Rodak, Waldemar Ślizień, Piotr Tylicki, Karolina Polewska, Alicja Kubanek, Alicja Dębska-Ślizień, Aleksandra Szydłowska, Leszek Tylicki, Bogdan Biedunkiewicz, Marcin Renke, Angelika Rucińska, Iwona Rosenberg
Publikováno v:
Medicina
Volume 57
Issue 7
Medicina, Vol 57, Iss 732, p 732 (2021)
Volume 57
Issue 7
Medicina, Vol 57, Iss 732, p 732 (2021)
Background and Objectives: The Pfizer-BioNTech (BNT162b2) COVID-19 mRNA vaccine has demonstrated excellent efficacy and safety in phase 3 trials. However, no dialyzed patients were included, and therefore safety data for this patient group is lacking